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Methods: All patients presenting to our multidisciplinary diabetic limb preservation service (June 2012 -June 2016 were enrolled in a prospective database. Inpatient costs and net margins (U.S. dollars) were calculated overall and for index admissions vs 30-day unplanned readmissions.
Results: A total of 249 admissions in 150 patients were included. Of these, 206 admissions were index admissions and 43 were 30-day readmissions. The most common reason for readmission was the foot wound (49%), followed by bypass wound (14%), renal (9%), and other systemic complications. Surgical interventions during readmission were common (47%) and included both podiatric (37%) and vascular (23%) interventions. The mean hospital cost per admission was $25,915 6 $1309 and did not differ between index admissions and readmissions ($25,649 6 $2384 vs $28,792 6 $4902; P ¼ .59). However, there was a trend toward lower hospital net margins after readmissions ($4978 6 $1010 vs $2700 6 $1289; P ¼ .07). The overall cost of care for patients requiring readmission was significantly higher than for patients who were not readmitted ($115,288 6 $19,325 vs $42,525 6 $3664; P < .001). During the course of the study period, DFU care at our institution cost $7.9 million, of which $1.2 million (15%) was attributable to readmission costs. Wound healing outcomes were favorable, with 78% of all wounds achieving healing by 1 year.
Conclusions: The cost of readmissions for DFU patients is just as high as the cost of the index admissions, but with lower hospital net margins. When it is extrapolated to national data, the 15% readmission cost burden that we report is equivalent to $210 million in hospital costs annually. Focused efforts at preventing readmissions in this population of high-risk patients are essential to reducing the overall costs of care associated with DFU.
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Methods: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs). MEDLINE and Embase up to February 2018 were searched. Studies were eligible for inclusion if they compared a growth factor vs placebo or standard care in patients with VLUs. Two reviewers independently selected RCTs and assessed risk of bias. The primary outcome measure was complete wound healing, and secondary outcomes were percentage reduction in wound area and adverse events. Pooled proportions of patients were calculated using a random-effects model, and heterogeneity among studies was assessed using inconsistency statistic and subgroup analyses.
Results: From 1460 studies, we included 12 RCTs (n ¼ 722). RCTs assessed platelets (platelet lysate, platelet gel, platelet-rich growth factor, platelet-rich plasma, platelet-rich fibrin), keratinocyte growth factor 2, endothelial growth factor, transforming growth factor b2, and granulocyte-macrophage colony-stimulating growth factor. There was no significant difference between any growth factor and placebo in complete wound healing (437/722 [59.97%] vs 285/722 [39.47%]; relative risk, 1.34, 95% confidence interval, 0.94-1.90, P ¼ .10; I 2 ¼ 71%, 11 trials; low-quality evidence). Subgroup analysis indicated that granulocyte-macrophage colony-stimulating growth factor held a significant increase in the number of wounds completely healed, whereas placebo demonstrated significantly more wounds completely healed compared with keratinocyte growth factor 2. When any growth factor was compared with placebo, there was a significant increase in percentage wound reduction by 48.72% (95% confidence interval, 39.14-58.30; P < .00001; I 2 ¼ 0%, four trials; low-quality evidence). There was no significant difference in overall adverse event rate.
Conclusions: In patients with chronic VLUs, growth factors have nonsignificant effect in complete wound healing. However, growth factors may increase percentage reduction in wound area. This suggests
